Press Release History - 2017

  • 16 Mar 2017
    ThromboGenics Business Update – FY 2016
  • 29 Jan 2017
    Regulated Information - Transparency Statement
  • 17 Jan 2017
    ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma
  • 10 Jan 2017
    ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)